Novo Nordisk is seeking to restrict compounded versions of its weight-loss drugs, Ozempic and Wegovy, by lobbying the FDA to add semaglutide to its Demonstrable Difficulties for Compounding list, citing safety concerns. This move aims to protect patients and ensure they receive FDA-approved medications, as compounded versions are often sold at significantly lower prices. The compounding industry disputes these claims, arguing that the action is more about protecting profits than patient safety.
Seems like the connection with the server has been lost. It can be due to poor or broken network. Please hang on while we're trying to reconnect...
Oh snap! Failed to reconnect with the server. This is typically caused by a longer network outage, or if the server has been taken down. You can try to reconnect, but if that does not work, you need to reload the page.
Oh man! The server rejected the attempt to reconnect. The only option now is to reload the page, but be prepared that it won't work, since this is typically caused by a failure on the server.